Skip to main
TWST

TWST Stock Forecast & Price Target

TWST Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 45%
Hold 18%
Sell 0%
Strong Sell 9%

Bulls say

Twist Bioscience is well positioned in the synthetic biology industry with its disruptive DNA synthesis platform. The company's strong customer commentary and a multiple growth drivers, including the increasing demand for real-world DNA validation and growth in AI-driven orders and drug discovery, make it a standout in the life science tools sector. Additionally, the company's focus on cost efficiency and potential for significant gross margin expansion through its Factory of the Future facility provide a clear path to profitability, further supporting its positive outlook.

Bears say

Twist Bioscience is a highly innovative synthetic biology company employing a proprietary semiconductor-based DNA synthesis platform to industrialize the engineering of biology, with a significant footprint in the fast-growing next-generation sequencing (NGS) market. While the company has a unique and disruptive technology and a strong growth trajectory, there are potential risks to their long-term success, including increased competition, market share erosion, and difficulty penetrating established markets. Furthermore, despite Twist's strong financial performance and impressive outlook, their reliance on AI-driven demand may also pose a risk to future growth potential.

TWST has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 45% recommend Buy, 18% suggest Holding, 0% advise Selling, and 9% predict a Strong Sell.

This aggregate rating is based on analysts' research of Twist Bioscience Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Twist Bioscience Corp (TWST) Forecast

Analysts have given TWST a Buy based on their latest research and market trends.

According to 11 analysts, TWST has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $94.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $94.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Twist Bioscience Corp (TWST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.